Search Results - "Soulie, Matthieu"

Refine Results
  1. 1
  2. 2
  3. 3

    Protein Alterations in Cardiac Ischemia/Reperfusion Revealed by Spatial-Omics by Mezger, Stephanie T P, Mingels, Alma M A, Soulié, Matthieu, Peutz-Kootstra, Carine J, Bekers, Otto, Mulder, Paul, Heeren, Ron M A, Cillero-Pastor, Berta

    “…Myocardial infarction is the most common cause of death worldwide. An understanding of the alterations in protein pathways is needed in order to develop…”
    Get full text
    Journal Article
  4. 4
  5. 5
  6. 6

    Abstract 103: Combined Dapagliflozine And Eplerenone Treatment Improve Cardiorenal Function In Rats With Chronic Kidney Disease by SOULIE, Matthieu, Manon, Durand, STEPHAN, Yohan, Lima Posada, Ixchel Quetzaliztli, Palacios-Ramirez, Roberto, Lopez-Andres, Natalia, Mulder, paul, Jaisser, Frederic

    Published in Hypertension (Dallas, Tex. 1979) (01-09-2023)
    “…Abstract only Background: Patients with chronic kidney disease (CKD) present higher risk of cardiovascular (CV) complications as well as renal function…”
    Get full text
    Journal Article
  7. 7

    NGAL is a Novel Target in Hypertension by Modulating the NCC-Mediated Renal Na Balance by Bonnard, Benjamin, El Moghrabi, Soumaya, Ueda, Kohei, Lattenist, Lionel, Soulie, Matthieu, López-Andrés, Natalia, Xhaard, Constance, Shimosawa, Tatsuo, Rossignol, Patrick, Jaisser, Frédéric

    Published in Hypertension (Dallas, Tex. 1979) (01-09-2023)
    “…The expression of NGAL/lcn2 (neutrophil gelatinase-associated lipocalin) is directly modulated by mineralocorticoid receptor activation but its role in blood…”
    Get full text
    Journal Article
  8. 8

    Mineralocorticoid receptor antagonists: A new therapeutic option for diabetic kidney disease by Girerd, Sophie, Soulie, Matthieu, Barrera-Chimal, Jonatan, Jaisser, Frédéric

    Published in M.S. Médecine sciences (24-04-2023)
    “…Diabetic kidney disease (DKD) and its associated cardiovascular morbidity represent a major complication in diabetic patients. Over the past two decades,…”
    Get more information
    Journal Article
  9. 9

    Abstract 080: The Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone Improves Diastolic Dysfunction In Preclinical Non-diabetic Chronic Kidney Disease by Lima Posada, Ixchel, STEPHAN, Yohan, Soulié, Matthieu, Palacios-Ramirez, Roberto, Bonnard, Benjamin, Kolkhof, Peter, Mulder, paul, Jaisser, Frederic

    Published in Hypertension (Dallas, Tex. 1979) (01-09-2023)
    “…Abstract only Background: The mineralocorticoid receptor (MR) plays an important role in the development of Chronic Kidney Disease (CKD) and its overactivation…”
    Get full text
    Journal Article
  10. 10

    386-P: Chronic Treatment with the Direct AMPK Activator PXL770 Improves Cardiac, Vascular, and Renal Function in Rodents with Diabetes-Related Cardiorenal Disease by STEPHAN, YOHAN, SOULIÉ, MATTHIEU, NICOL, LIONEL, GLUAIS-DAGORN, PASCALE, HALLAKOU-BOZEC, SOPHIE, MULDER, PAUL

    Published in Diabetes (New York, N.Y.) (01-06-2021)
    “…Introduction: PXL770 is a direct AMP kinase activator. In models of T2DM and NASH, PXL770 improves hyperglycemia and dyslipidemia and reduces: steatosis,…”
    Get full text
    Journal Article
  11. 11
  12. 12
  13. 13
  14. 14

    Altered ECG parameters with loss of cardiac variability and prolonged QTc in a non-diabetic chronic kidney disease rat model by Soulié, Matthieu, Cambier, Agathe, Fontana-Pires, Leandro, Lima-Posada, Ixchel, Jaisser, Frédéric

    Published in Archives of cardiovascular diseases (01-06-2024)
    “…Patients with Chronic Kidney Disease (CKD) have increased risk of cardiovascular mortality from arrhythmias and sudden cardiac death. The pathogenesis by which…”
    Get full text
    Journal Article
  15. 15

    1963-P: Short- and Long-Term Empagliflozin Treatment Improves Cardiac Function in Rats with Chronic Heart Failure by SOULIÉ, MATTHIEU, STEPHAN, YOHAN, NICOL, LIONEL, HENRY, JEAN-PAUL, RICHARD, VINCENT, PIEPER, MICHAEL, MULDER, PAUL

    Published in Diabetes (New York, N.Y.) (01-06-2020)
    “…Introduction: The SGLT2 inhibitor empagliflozin (EMPA) exerts beneficial cardiovascular effects in type-2 diabetes, but whether this occurs in chronic heart…”
    Get full text
    Journal Article
  16. 16
  17. 17
  18. 18

    Combined dapagliflozine and eplerenone treatment improve cardiorenal function in rats with chronic kidney disease by Stephan, Yohan, Soulié, Matthieu, Durand, Manon, Lima-Posada, Ixchel, Palacios-Ramirez, Roberto, Nicol, Lionel, Lopez-Andres, Natalia, Mulder, Paul, Jaisser, Frédéric

    Published in Archives of cardiovascular diseases (01-06-2024)
    “…Patients with chronic kidney disease (CKD) present higher risk of cardiovascular (CV) complications as well as renal function decline. The DAPA-CKD trial…”
    Get full text
    Journal Article
  19. 19
  20. 20

    Cover Image by Lachaux, Marianne, Soulié, Matthieu, Hamzaoui, Mouad, Bailly, Anaëlle, Nicol, Lionel, Rémy‐Jouet, Isabelle, Renet, Sylvanie, Vendeville, Cathy, Gluais‐Dagorn, Pascale, Hallakou‐Bozec, Sophie, Monteil, Christelle, Richard, Vincent, Mulder, Paul

    Published in Endocrinology, diabetes & metabolism (22-07-2020)
    “…Cover caption The cover image is based on the Original Article “ Short‐ And Long‐Term Administration of Imeglimin Counters Cardiorenal Dysfunction in a Rat…”
    Get full text
    Journal Article